Eupraxia Pharmaceuticals's total assets for Q1 2026 were C$145.46M, an increase of 69.15% from the previous quarter. EPRX total liabilities were C$9.17M for the fiscal quarter, a 61.10% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.